Addressing blood glucose levels is continuing to be a major factor in health care despite the dietary and therapeutic measures being implemented in so many health protocols.
During my many conversations and visits with practitioners, I’m often asked specific questions about the benefits of GENZOGENOL for blood-sugar control and the metrics used to measure its effects from research. I often cite the study below on our feature ingredient, ENZOGENOL, which goes into the detail practitioners are asking for. GENZOGENOL contains a dose equivalent to the medium dose mentioned below (approx. 210mg per 100kg). In addition it contains other ingredients highly notes for effective for blood-glucose control (please see attached).
This is a bit of long read but worthwhile especially when you consider that it also effectively addresses systemic inflammation, a condition commonly associated with diabetes.
Mouse diabetes trial
In 2014 a research group in Korea published initial investigations of ENZOGENOL’s antidiabetic effects in a mouse model of type-2-diabetes mellitus11. The researchers found that ENZOGENOL improved diabetes related metabolic changes including improved glucose tolerance, reduced glycosylated hemoglobin levels, as well as lower insulin and glucagon levels in the blood, and improved liver lipid profiles.
In this study the diabetic mice received ENZOGENOL at 12.5, 25 and 50 mg/kg body weight, equivalent to 1, 2.1 and 4.2 mg/kg body weight in humans. Both, medium and high dose treatments were effective at improving glucose and lipid metabolism. In detail, ENZOGENOL medium-dose treatment (equivalent to ≈210 mg for a 100 kg human) decreased fasting blood glucose levels by 27% at 4 weeks and 20% at 6 weeks.
The high dose treatment (≈420 mg for a 100 kg human) decreased fasting blood glucose levels by 37% and 41% at 4 and 6 weeks, respectively. A two hour oral glucose tolerance test showed that ENZOGENOL significantly improved glucose clearance from the blood indicating a significant decrease in insulin resistance.
In untreated diabetic controls HbA1C, serum insulin and glucagon levels are elevated. ENZOGENOL at 25 and 50 mg/kg significantly reduced HbA1c by 35.2% and 57.8%, serum insulin by 60.1% and 70% and glucagon levels by 46.1% and 66.8%, respectively.
Investigating parameters of lipid metabolism showed that ENZOGENOL increased activation of AMPK (AMP activated protein kinase). This liver enzyme stimulates hepatic lipid oxidation, and inhibits cholesterol and triglyceride synthesis. Reduced AMPK activity in diabetes leads to a negative liver fatty acid profile. Yet ENZOGENOL treatment was able to normalize triglycerides, total cholesterol and HDL cholesterol to non-diabetic levels in the mice. Further effects on liver enzymes included increased amounts of glucokinase and glycogen synthase thereby improving glucose clearance from the blood, and reduced Glucose-6-Phosphatase and Phosphoenol-pyruvate-carboxykinase levels which reduced unnecessary glucose synthesis.
In conclusion, using a mouse-model of type-2-diabetes this study showed that ENZOGENOL has potential hypoglycaemic effects by modulating the expression of hepatic glucose-regulating enzymes, and enzymatic activity of AMPK in the liver.
ENZOGENOL is the feature ingredient in GENZOGENOL which is also formulated with Astaxanthin, Pterostilbene, Resveratrol, Green Tea Extract, Quercetin and Lecithin.
Integra Nutrition – Longevity Sciences is an award winning brand natural health practitioners have trusted for over 25 years. Our products are Healthy Aging supplement solutions and their ingredients have undergone numerous studies and we present them with utmost confidence.
Order and discover the benefits for you and your patients. On behalf of our team, we look forward to working with you.